CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic CancerSam Z. Thalji, Susan Tsai, Mandana Kamgar et al.|Annals of Surgical Oncology|2023Cited by 14
Outcomes of palliative‐intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma CollaborativeSam Z. Thalji, Callisia N. Clarke, Kathleen K. Christians et al.|Journal of Surgical Oncology|2020Cited by 13
Outcomes of plastic surgical reconstruction in extremity and truncal soft tissue sarcoma: Results from the US Sarcoma CollaborativeSam Z. Thalji, Harveshp Mogal, Cecilia G. Ethun et al.|Journal of Surgical Oncology|2022Cited by 6
Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantitySam Z. Thalji, Susan Tsai, Mohammed Aldakkak et al.|Journal of Surgical Oncology|2023Cited by 4
Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic CancerSam Z. Thalji, Susan Tsai, Deemantha G. Fernando et al.|Annals of Surgery|2023Cited by 4